Today's Top Alzheimer's News
May 29, 2014
The struggle with genetic testing for Alzheimer's, President Obama announces new funding for head trauma research, and a new eye test for Alzheimer's on the horizon (read more).
- A May 29, 2014 Portland Tribune article explored ethical and personal struggles with genetic testing for diseases like Alzheimer's and Huntington's. According to the article, "Nancy Wexler, a geneticist who helped discover the Huntington’s gene, coined the phrase Tiresias Complex to describe the decision facing those who might have a test for a fatal illness for which there is no cure. In Greek mythology, Tiresias was a blind prophet reluctant to reveal to King Oedipus how and when the king would die. Tiresias felt such knowledge, without the power to change the future, could only lead to sorrow…Epstein says the question of which is better for your health — to test or not to test — is not a simple one. A positive test for Alzheimer’s or Huntington’s might lead a patient to make lifestyle changes to improve his or her health. But there’s a similar argument to be made, he says, for not getting tested."
- A May 28, 2014 The Hill article reported that President Obama will hold a White House summit on concussion research where he will announce "millions in new funding for concussion research and prevention efforts."
Research and science
- A May 29, 2014 Design News article reported that a Boston based startup has developed a new eye test for Alzheimer's. According to the article, "A Massachusetts-based startup called Cognoptix has created a machine that uses a novel way -- through abnormalities in the eye -- to detect Alzheimer's disease earlier in its progression and more accurately… It also could provide pharmaceutical companies with a competitive advantage in securing new Alzheimer's drug approvals, Ron Trahan, Cognoptix's public relations counsel and spokesman, told Design News."
- A May 28, 2014 Boston Business Journal article reported that "AZTherapies, a privately-held biotech firm, plans to start late-stage global trial in Alzheimer’s disease of a combination of potential drugs it reformulated use technology it licensed from Massachusetts General Hospital."